Matthew Taylor
Stock Analyst at Jefferies
(3.42)
# 878
Out of 4,905 analysts
175
Total ratings
61.68%
Success rate
11.52%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $123.67 | +17.25% | 14 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $13.90 | +7.95% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $75.96 | +35.60% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $76.49 | -8.48% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $284.23 | -21.54% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $89.61 | -15.19% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $3.14 | +3,880.89% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $154.47 | -21.67% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $3.09 | +353.07% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $14.77 | +204.67% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.58 | -13.78% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $11.13 | +376.19% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $7.24 | +231.49% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $389.40 | -11.40% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $93.19 | +39.50% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $230.38 | -0.16% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $16.64 | +20.23% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $47.64 | +78.42% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $56.34 | +33.12% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $257.92 | -5.01% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $27.77 | +123.26% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $111.06 | +89.09% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $10.49 | +14.39% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $83.89 | +49.00% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $103.64 | -51.76% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $518.62 | -59.51% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $41.98 | +128.68% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.87 | +274.33% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $178.85 | +48.73% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $8.69 | +84.12% | 2 | Jul 19, 2017 |
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $123.67
Upside: +17.25%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $13.90
Upside: +7.95%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $75.96
Upside: +35.60%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $76.49
Upside: -8.48%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $284.23
Upside: -21.54%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $89.61
Upside: -15.19%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $3.14
Upside: +3,880.89%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $154.47
Upside: -21.67%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $3.09
Upside: +353.07%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $14.77
Upside: +204.67%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.58
Upside: -13.78%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $11.13
Upside: +376.19%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $7.24
Upside: +231.49%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $389.40
Upside: -11.40%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $93.19
Upside: +39.50%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $230.38
Upside: -0.16%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $16.64
Upside: +20.23%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $47.64
Upside: +78.42%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $56.34
Upside: +33.12%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $257.92
Upside: -5.01%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $27.77
Upside: +123.26%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $111.06
Upside: +89.09%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $10.49
Upside: +14.39%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $83.89
Upside: +49.00%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $103.64
Upside: -51.76%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $518.62
Upside: -59.51%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $41.98
Upside: +128.68%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.87
Upside: +274.33%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $178.85
Upside: +48.73%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.69
Upside: +84.12%